^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Eligard (leuprolide acetate)

    i
    Other names: SOU 375, LA 2575, SOT-375, TOL2506, LA2575, LA-2575, SOT375, SOT 375, SOU375, SOU-375, TOL 2506, TOL-2506
    Company:
    Daewoong Pharma, Recordati, Sanofi, Tolmar
    Drug class:
    GnRH agonist
    Related drugs:
    24d
    Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers (clinicaltrials.gov)
    P2, N=21, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eligard (leuprolide acetate) • Nubeqa (darolutamide) • Viadur (leuprorelin implant)
    2ms
    ImmunoADAPT: Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer (clinicaltrials.gov)
    P2, N=33, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Sep 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor)
    |
    ER positive
    |
    Ibrance (palbociclib) • tamoxifen • Bavencio (avelumab) • Eligard (leuprolide acetate) • goserelin acetate
    3ms
    The COSMYC Trial (COmbined Suppression of MYC) (clinicaltrials.gov)
    P2, N=50, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Xtandi (enzalutamide) • Eligard (leuprolide acetate) • triptorelin • goserelin acetate • ZEN-3694 • Firmagon (degarelix) • Orgovyx (relugolix)
    3ms
    Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study (clinicaltrials.gov)
    P3, N=27, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial primary completion date
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    |
    Eligard (leuprolide acetate) • Nubeqa (darolutamide) • triptorelin • goserelin acetate • Viadur (leuprorelin implant)
    3ms
    Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    New P2 trial
    |
    Eligard (leuprolide acetate) • Nubeqa (darolutamide) • triptorelin • goserelin acetate • Firmagon (degarelix) • Orgovyx (relugolix)
    4ms
    The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's (clinicaltrials.gov)
    P2, N=180, Active, not recruiting, Weill Medical College of Cornell University | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eligard (leuprolide acetate)
    5ms
    PROMPT: Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer (clinicaltrials.gov)
    P2, N=77, Recruiting, McGill University Health Centre/Research Institute of the McGill University Health Centre | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2023 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Eligard (leuprolide acetate)
    6ms
    Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Icahn School of Medicine at Mount Sinai
    New P2 trial
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • Decipher Prostate Cancer Test
    |
    Keytruda (pembrolizumab) • Eligard (leuprolide acetate) • Nubeqa (darolutamide) • leuprolide acetate for depot suspension
    6ms
    Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy (clinicaltrials.gov)
    P2, N=118, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed | Trial completion date: Jul 2025 --> Jul 2024
    Trial completion • Trial completion date
    |
    abiraterone acetate • prednisone • Eligard (leuprolide acetate) • apalutamide
    7ms
    OVELIA: Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer (clinicaltrials.gov)
    P3, N=250, Active, not recruiting, Tolmar Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    tamoxifen • letrozole • anastrozole • exemestane • Eligard (leuprolide acetate)
    7ms
    The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's (clinicaltrials.gov)
    P2, N=180, Recruiting, Weill Medical College of Cornell University | Trial completion date: May 2026 --> Aug 2026 | Trial primary completion date: May 2026 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    Eligard (leuprolide acetate)
    7ms
    RATIONAL-PCS: Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC) (clinicaltrials.gov)
    P2, N=162, Not yet recruiting, Ontario Clinical Oncology Group (OCOG) | Initiation date: Apr 2025 --> Jul 2025
    Trial initiation date
    |
    Eligard (leuprolide acetate)